Figure 11.
Hemolytic effect (A) and platelet aggregating capacity (B) for the treatments with 0.7% (w/v) PVA, 20 μg/mL GO-Ag NPs. In addition, commercial treatments also were evaluated. ∗, p < 0.05.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.